1.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International
consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology.
2015;85:177-89.
2.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal
multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7.
3.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Lancet. 2004;364:2106-12.
4.
Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol.
2012;11:535-44.
5.
Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic
cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing
remitting or primary progressive multiple sclerosis. PLoS One. 2013;8:e61835.
6.
Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenetic
and therapeutic implications. Brain Pathol. 2014;24:67-73.
7.
Kothur K, Wienholt L, Brilot F, Dale RC. CSF cytokines/chemokines as biomarkers in
neuroinflammatory CNS disorders: a systematic review. Cytokine. 2016;77:227-37.
8.
Gunther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling
through the IL-36 receptor. J Immunol. 2014;193:921-30.
9.
Chu M, Wong CK, Cai Z, Dong J, Jiao D, Kam NW, et al. Elevated expression and pro-inflammatory
activity of IL-36 in patients with systemic lupus erythematosus. Molecules. 2015;20:19588-604.
10.
Alsahebfosoul F, Jahanbani-Ardakani H, Ghavimi R, Sedaghat N, Etemadifar M. Serum
level of interleukin 36 in patients with multiple sclerosis. J Immunoassay Immunochem.
2018;39:558-64.
11.
Russell SE, Horan RM, Stefanska AM, Carey A, Leon G, Aguilera M, et al. IL-36alpha
expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal
Immunol. 2016;9:1193-204.
12.
Nishida A, Hidaka K, Kanda T, Imaeda H, Shioya M, Inatomi O, et al. Increased expression
of interleukin-36, a member of the interleukin-1 cytokine family, in inflammatory
bowel disease. Inflamm Bowel Dis. 2016;22:303-14.
13.
Otobe S, Sugaya M, Nakajima R, Oka T, Takahashi N, Kabasawa M, et al. Increased interleukin-36gamma
expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/sezary
syndrome. J Dermatol. 2018;45:468-71.
14.
Mahil SK, Catapano M, Di Meglio P, Dand N, Ahlfors H, Carr IM, et al. An analysis
of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates
IL-36 as a psoriasis therapeutic target. Sci Transl Med. 2017;9:eaan2514.
15.
Di Caprio R, Balato A, Caiazzo G, Lembo S, Raimondo A, Fabbrocini G, et al. IL-36
cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res. 2017;309:673-8.
16.
Yang CS, Zhang DQ, Wang JH, Jin WN, Li MS, Liu J, et al. Clinical features and sera
anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the
central nervous system from Tianjin, China. CNS Neurosci Ther. 2014;20:32-9.
17.
Bridgewood C, Stacey M, Alase A, Lagos D, Graham A, Wittmann M. IL-36gamma has proinflammatory
effects on human endothelial cells. Exp Dermatol. 2017;26:402-8.
18.
Dunn E, Sims JE, Nicklin MJ, O'Neill LA. Annotating genes with potential roles in
the immune system: six new members of the IL-1 family. Trends Immunol. 2001;22:533-6.
19.
Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and
IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB
and MAPKs. J Biol Chem. 2004;279:13677-88.
20.
Dietrich D, Martin P, Flacher V, Sun Y, Jarrossay D, Brembilla N, et al. Interleukin-36
potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce
pro-inflammatory cytokines. Cytokine. 2016;84:88-98.
21.
Bozoyan L, Dumas A, Patenaude A, Vallieres L. Interleukin-36gamma is expressed by
neutrophils and can activate microglia, but has no role in experimental autoimmune
encephalomyelitis. J Neuroinflammation. 2015;12:173.
22.
Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, et al. IL-36R
ligands are potent regulators of dendritic and T cells. Blood. 2011;118:5813-23.
23.
Foster AM, Baliwag J, Chen CS, Guzman AM, Stoll SW, Gudjonsson JE, et al. IL-36 promotes
myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol.
2014;192:6053-61.
24.
Ramadas RA, Ewart SL, Medoff BD, LeVine AM. Interleukin-1 family member 9 stimulates
chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol.
2011;44:134-45.
25.
Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art
and emerging therapies. Nat Rev Neurol. 2014;10:493-506.
26.
Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil
protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in
mouse brain. Ann Neurol. 2012;71:323-33.
27.
Yang T, Wang S, Zheng Q, Wang L, Li Q, Wei M, et al. Increased plasma levels of epithelial
neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica.
BMC Neurol. 2016;16:96.
28.
Penha R, Higgins J, Mutamba S, Barrow P, Mahida Y, Foster N. IL-36 receptor is expressed
by human blood and intestinal T lymphocytes and is dose-dependently activated via
IL-36beta and induces CD4+ lymphocyte proliferation. Cytokine. 2016;85:18-25.
29.
Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O'Toole M, et al. Inter-regulation
of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis
pathogenesis. J Invest Dermatol. 2011;131:2428-37.
30.
Wang H, Wang K, Wang C, Xu F, Zhong X, Qiu W, et al. Cerebrospinal fluid high-mobility
group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation.
2013;20:113-8.
31.
Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine
profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16:1443-52.
32.
Barros PO, Cassano T, Hygino J, Ferreira TB, Centuriao N, Kasahara TM, et al. Prediction
of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced
during remission phase. Clin Exp Immunol. 2016;183:480-9.